Ефективність терапії статинами у жінок
DOI:
https://doi.org/10.37987/1997-9894.2015.2(188).222515Ключові слова:
жінки, терапія, статини, первинна профілактика, вторинна профілактикаАнотація
У статті наведено аналіз результатів численних міжнародних досліджень щодо ефективності терапії статинами у жінок різних вікових груп. Показано ефективність застосування статинів у жінок з метою вторинної профілактики серцево-судинних ускладнень, в той час як щодо первинної профілактики залишається багато невирішених питань.Посилання
Scandinavian Simvastatin Survival Study Group et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. – 1994. – Т. 344, №8934. – С. 1383–1389.
Shepherd J. et al. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia // New Engl. J. of Medicine. – 1995. – Т. 333, №20. – С. 1301–1308.
Sacks F.M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels // New Engl. J. of Medicine. – 1996. – Т. 335, №14. – С. 1001–1009.
Downs J.R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS // JAMA. – 1998. – Т. 279, №20. – С. 1615–1622.
Hague W. et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study // Am. Heart J. – 2003. – Т. 145, №4. – С. 643–651.
Schwartz G.G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // JAMA. – 2001. – Т. 285, №13. – С. 1711–1718.
Yusuf S. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary // Lancet. – 2002. – Т. 360, №9326. – С. 7–22.
Ridker P.M. The JUPITER trial results, controversies, and implications for prevention // Circulation: Cardiovascular Quality and Outcomes. – 2009. – Т. 2, №3. – С. 279–285.
Pedersen T.R. et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study // Am. J. of Cardiology. – 2004. – Т. 94, №6. – С. 720–724.
Wenger N.K. et al. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study // Heart. – 2008. – Т. 94, №4. – С. 434–439.
Sever P.S., Poulter N.R., Dahlof B. et al., the ASCOT investigators: Reduction in cardiovascular events with atorvastatin in 2,532 patients with Type 2 diabetes // Diabetes Care. – 2005. – Т. 28. – С. 1151–1157.
Brugts J.J., Yetgin T., Hoeks S.E. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials // BMJ. – 2009. – Т. 338.
Protocol No. A2581051: Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women: a randomized evaluation of atorvastatin versus placebo (CASHMERE). – www.clinicaltrials.gov/ct/show/NCT00163163?order=1 (Accessed 29 March 2008).
Nakaya N. et al. Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese // Drugs & Aging. – 2011. – Т. 28, №9. – С. 681–692.
Miettinen T.A. et al. Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival Study (4S) // Circulation. – 1997. – Т. 96, №12. – С. 4211–4218.
Walsh J.M.E., Pignone M. Drug treatment of hyperlipidemia in women // JAMA. – 2004. – Т. 291, №18. – С. 2243–2252.
Mora S. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials //Circulation. – 2010. – Т. 121, №9. – С. 1069–1077.
Lewis S.J. et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial // J. of the Am. College of Cardiology. – 1998. – Т. 32, №1. – С. 140–146.
Hague W., Forder P., Simes J. et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study // Am. Heart J. –2003 Apr. – Т. 145 (4). – С. 643–651.
Shepherd J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial // Lancet. – 2002. – Т. 360, №9346. – С. 1623–1630.
Petretta M., Costanzo P., Perrone-Filardi P., Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis // Int. J. of Cardiology. – 2010. – Т. 138 (1). – С. 25–31.
Gutierrez J. et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis // Archives of Internal Medicine. – 2012. – Т. 172, №12. – С. 909–919.
Kostis W.J. et al. Meta-analysis of statin effects in women versus men // J. of the Am. College of Cardiology. – 2012. – Т. 59, №6. – С. 572–582.
Мітченко О.І. Методичні рекомендації Української асоціації кардіологів. Дисліпідемії : діагностика, профілактика та лікування. – К., 2011. – С. 1–48.
Reiner Z. et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. – 2011. – Т. 32, №14. – С. 1769–1818.
Santos R.D. et al. Low-and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2 // Am. Heart J. – 2009. – Т. 158, №5. – С. 860–866.
Victor B.M. et al. Gender Differences in Achieving Optimal Lipid Goals in Patients With Coronary Artery Disease // Am. J. of Cardiology. – 2014. – Т. 113, №10. – С. 1611–1615.
Singh M. et al. Time Trends of Gender-Based Differences in Lipid Goal Attainments During Secondary Prevention of Coronary Artery Disease: Results of a 5-Year Survey // Am. J. of Therapeutics. – 2013. – Т. 20, №6. – С. 613–617.
Reibis R.K. et al. Elevated risk profile of women in secondary prevention of coronary artery disease: a 6-year survey of 117,913 patients // J. of Women's Health. – 2009. – Т. 18, №8. – С. 1123–1131.
Schrott H.G., Bittner, V., Vittinghoff E. et al. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS) // JAMA. – 1997. – Т. 277, №16. – С. 1281–1286.
Dallongevillle, J., De Bacquer D., Heidrich J. et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event // Heart. – 2010. – Т. 96, №21. – С. 1744–1749.
Chen C.Y., Chuang S.Y., Fang C.C. et al. Gender difference in statin intervention on blood lipid control among patients with coronary heart disease // Int. J. of Gerontology. – 2013. – Т. 7, №2. – С. 116–121.
Takahashi E., Moriyama K., Yamakado M. Status of dyslipidemia treatment in Japanese adults: an analysis of the 2009 Japan Society of Ningen Dock database // Internal Medicine (Tokyo, Japan). – 2012. – Т. 52, №3. – С. 295–301.
Merz C.N.B. The Yentl syndrome is alive and well // Eur. Heart J. – 2011. – Т. 32, №11. – С. 1313–1315.
Persson L., Henriksson P., Westerlund E. et al. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp (a) or bile acid synthesis in women // Arteriosclerosis, Thrombosis, and Vascular Biology. – 2012. – Т. 32, №3. – С. 810–814.
De Marinis E., Martini C., Trentalance A., Pallottini V. Sex differences in hepatic regulation of cholesterol homeostasis // J. of Endocrinology. – 2008. – Т. 198, №3. –С. 635–643.
Saltiki K., Doukas C., Kanakakis J. et al. Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen // Maturitas. – 2006. – Т. 55, №1. – С. 51–57.
Harlow S.D., Gass M., Hall J.E. et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging // Menopause. – 2012. – Т. 19 (4). – С. 387–395.
Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk // Hum. Reprod. – 2003. – Т. 18 (8). – С. 1570–1573.
Crandall C.J., Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review // Endocrinol. Metab. Clin. North Am. – 2013. – Т. 42 (2). – С. 227–253.
Derby C.A., Crawford S.L., Pasternak R.C. et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation // Am. J. Epidemiol. – 2009. – Т. 169 (11). – С. 1352–1361.
Greenfield J.R., Samaras K., Campbell L.V. et al. Physical activity reduces genetic susceptibility to increased central systolic pressure augmentation: a study of female twins // J. of the Am. College of Cardiology. – 2003. – Т. 42, №2. – С. 264–270.
De Villiers T.J., Gass M.L.S., Haines C.J. et al. Global consensus statement on menopausal hormone therapy // Climacteric. – 2013. – Т. 16, №2. – С. 203–204.
Prentice R.L. Postmenopausal Hormone Therapy and the Risks of Coronary Heart Disease, Breast Cancer, and Stroke // Seminars in Reproductive Medicine. – 2014. – Т. 32, №6. – С. 419–425.
Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial // JAMA. – 2002. – Т. 288, №3. – С. 321–333.
Rossouw J.E., Anderson G.L., Prentice R.L. et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial // JAMA. – 2002. – Т. 288, №3. – С. 321–333.
Manson J.E., Chlebowski R.T., Stefanick M.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials // JAMA. – 2013. – Т. 310, №13. –С. 1353–1368.
Gurney E.P., Nachtigall M.J., Nachtigall L.E., Naftolin F. The Women's Health Initiative trial and related studies: 10 years later: A clinician's view // J. of Steroid Biochemistry and Molecular Biology. – 2014. – Т. 142. – С. 4–11.
Lacey Jr J.V. The WHI ten year's later: An epidemiologist's view // J. of Steroid Biochemistry and Molecular Biology. – 2014. – Т. 142. – С. 12–15.
Dessapt A.L., Gourdy P. Menopause and cardiovascular risk // J. de Gynecologie, Obstetrique et Biologie de la Reproduction. – 2012. – Т. 41, №7 (Suppl). – С. F13–19.
Schnatz P.F. Hormonal therapy: does it increase or decrease cardiovascular risk? // Obstetrical & Gynecological Survey. – 2006. – Т. 61, №10. – С. 673–681.
Grady D., Herrington D., Bittner V. et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) // JAMA. – 2002. – Т. 288, №1. – С. 49–57.
Paggi P., Davidson M., Callister T.Q. et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women beyond endorsed lipid lowering with EBT scanning (BELLES) // Circulation. – 2005. – Т. 112, №4. – С. 563–571.
Herrington D.M. et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) // Circulation. – 2002. – Т. 105, №25. – С. 2962–2967.
Li L., Sun T., Zhang P. et al. Statins for primary prevention of venous thromboembolism //Cochrane Database Syst. Rev. – 2011. – Т. 12.
Hsia J., Klouj A., Prasad A. et al. Progression of coronary calcification in healthy postmenopausal women // BMC cardiovascular disorders. – 2004. – Т. 4, №1. – С. 21.
Pellegrini C.N., Vittinghoff E., Lin F. et al. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial // Heart. – 2009. – Т. 95, №9. – С. 704–708.
Lobo R.A. Postmenopausal hormones and coronary artery disease: potential benefits and risks // Climacteric. – 2007. – Т. 10, №S2. – С. 21–26.
Ozsener S., Sendag F., Koc T. et al. Comparison of Continuous Combined Hormone Replacement Therapy, HMG-CoA Reductase Inhibitor and Combined Treatment for the Management of Hypercholesterolemia in Postmenopausal Women // J. of Obstetrics and Gynaecology Research. – 2001. – Т. 27, №6. – С. 353–358.
Shepherd J., Packard C., Walker J. et al. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy // Current Med. Research and Opinion. – 2004. – Т. 20, №10. – С. 1571–1578.
Koh K.K., Schenke W.H., Waclawiw M.A. et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women // Circulation. –2002. – Т. 105, №13. – С. 1531–1533.
Sbarouni E., Kyriakides Z.S., Kremastinos D.T. Effect of simvastatin on serum C-reactive protein during hormone replacement therapy // Am. J. of Cardiology. – 2004. – Т. 93, №2. – С. 217–218.
Dobrzycka B., Dobrzycki S., Lenczewski A. et al. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on lipid levels in hypercholesterolemic women // Ginekologia Polska. – 2003. – Т. 74, №9. – С. 937–942.
